| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 22/04/2024 | 22:01 | Business Wire | Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K | NASDAQ:XCUR | Exicure Inc |
| 06/03/2024 | 18:15 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:XCUR | Exicure Inc |
| 04/03/2024 | 23:37 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:XCUR | Exicure Inc |
| 05/02/2024 | 22:16 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:XCUR | Exicure Inc |
| 05/02/2024 | 22:01 | Business Wire | Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis | NASDAQ:XCUR | Exicure Inc |
| 28/11/2023 | 22:01 | Business Wire | Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q | NASDAQ:XCUR | Exicure Inc |
| 14/11/2023 | 22:28 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB | NASDAQ:XCUR | Exicure Inc |
| 29/09/2023 | 23:05 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:XCUR | Exicure Inc |
| 23/08/2023 | 15:48 | Business Wire | Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors | NASDAQ:XCUR | Exicure Inc |
| 11/08/2023 | 22:33 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:XCUR | Exicure Inc |
| 11/08/2023 | 22:01 | Business Wire | Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update | NASDAQ:XCUR | Exicure Inc |
| 14/07/2023 | 22:01 | Business Wire | Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update | NASDAQ:XCUR | Exicure Inc |
| 28/06/2023 | 22:22 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:XCUR | Exicure Inc |
| 28/06/2023 | 00:20 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:XCUR | Exicure Inc |
| 27/06/2023 | 23:17 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:XCUR | Exicure Inc |
| 14/06/2023 | 22:47 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:XCUR | Exicure Inc |
| 26/05/2023 | 22:01 | Business Wire | Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives | NASDAQ:XCUR | Exicure Inc |
| 15/05/2023 | 23:17 | Edgar (US Regulatory) | Notification That Quarterly Report Will Be Submitted Late (nt 10-q) | NASDAQ:XCUR | Exicure Inc |
| 04/05/2023 | 22:01 | Business Wire | Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld | NASDAQ:XCUR | Exicure Inc |
| 01/05/2023 | 23:26 | Edgar (US Regulatory) | Amended Annual Report (10-k/a) | NASDAQ:XCUR | Exicure Inc |
| 27/03/2023 | 22:37 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:XCUR | Exicure Inc |
| 27/03/2023 | 22:01 | Business Wire | Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update | NASDAQ:XCUR | Exicure Inc |
| 24/02/2023 | 23:10 | Business Wire | Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors | NASDAQ:XCUR | Exicure Inc |
| 14/12/2022 | 13:18 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:XCUR | Exicure Inc |
| 14/12/2022 | 11:00 | Business Wire | Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements | NASDAQ:XCUR | Exicure Inc |
| 14/11/2022 | 22:47 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:XCUR | Exicure Inc |
| 14/11/2022 | 22:01 | Business Wire | Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update | NASDAQ:XCUR | Exicure Inc |
| 10/11/2022 | 23:15 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:XCUR | Exicure Inc |
| 26/09/2022 | 22:01 | Business Wire | Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives | NASDAQ:XCUR | Exicure Inc |
| 01/09/2022 | 13:00 | Business Wire | Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference | NASDAQ:XCUR | Exicure Inc |